Home > News > Nanogen Completes Acquisition of SynX Pharma Inc.
April 21st, 2004
Nanogen Completes Acquisition of SynX Pharma Inc.
Nanogen, Inc. and SynX Pharma Inc. announced today that Nanogen completed its acquisition of all of the common shares and debentures of SynX, pursuant to a plan of arrangement, in exchange for shares of Nanogen common stock. SynX is now a wholly-owned subsidiary of Nanogen.
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014
Graphene industry takes further step towards commercialisation with Haydale IPO listing March 19th, 2014
Tiny particles could help verify goods: Chemical engineers hope smartphone-readable microparticles could crack down on counterfeiting April 15th, 2014
A molecular approach to solar power: Switchable material could harness the power of the sun ó even when itís not shining April 15th, 2014
Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014
Biologists Develop Nanosensors to Visualize Movements and Distribution of Plant Stress Hormone April 15th, 2014